AR065657A1 - DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS. - Google Patents

DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS.

Info

Publication number
AR065657A1
AR065657A1 ARP080100964A ARP080100964A AR065657A1 AR 065657 A1 AR065657 A1 AR 065657A1 AR P080100964 A ARP080100964 A AR P080100964A AR P080100964 A ARP080100964 A AR P080100964A AR 065657 A1 AR065657 A1 AR 065657A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
arthritis
halo
alkyl
cartilage
Prior art date
Application number
ARP080100964A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39530136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065657(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR065657A1 publication Critical patent/AR065657A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP080100964A 2007-03-07 2008-03-07 DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS. AR065657A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89346407P 2007-03-07 2007-03-07

Publications (1)

Publication Number Publication Date
AR065657A1 true AR065657A1 (es) 2009-06-24

Family

ID=39530136

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100964A AR065657A1 (es) 2007-03-07 2008-03-07 DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS.

Country Status (17)

Country Link
US (1) US8580832B2 (OSRAM)
EP (1) EP2134698A1 (OSRAM)
JP (1) JP2010520308A (OSRAM)
KR (1) KR20090128454A (OSRAM)
CN (1) CN101679327A (OSRAM)
AR (1) AR065657A1 (OSRAM)
AU (1) AU2008222755B2 (OSRAM)
BR (1) BRPI0808776A2 (OSRAM)
CA (1) CA2680212A1 (OSRAM)
CL (1) CL2008000667A1 (OSRAM)
EA (1) EA016887B1 (OSRAM)
IL (1) IL200759A0 (OSRAM)
MX (1) MX2009009520A (OSRAM)
NZ (1) NZ579417A (OSRAM)
TW (1) TW200902506A (OSRAM)
UA (1) UA98484C2 (OSRAM)
WO (1) WO2008109737A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
CN101848893B (zh) 2007-09-14 2012-06-06 奥梅-杨森制药有限公司 1,3-二取代的4-(芳基-x-苯基)-1h-吡啶-2-酮
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
MX2011002042A (es) 2008-09-02 2011-06-20 Ortho Mcneil Janssen Pharm Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico.
ES2466341T3 (es) 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2430022B1 (en) 2009-05-12 2013-11-20 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
JPWO2011016501A1 (ja) * 2009-08-04 2013-01-10 武田薬品工業株式会社 癌の予防ないし治療薬
US8927297B2 (en) * 2009-08-11 2015-01-06 Janssen Pharmaceutica N.V. Methods to measure dissociation rates for ligands that form reversible covalent bonds
US8187871B2 (en) * 2009-08-11 2012-05-29 Janssen Pharmaceutica N.V. Co-crystallization of ERR-α with a ligand that forms a reversible covalent bond
WO2011075565A1 (en) * 2009-12-18 2011-06-23 Janssen Pharmaceutica Nv SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-Aα MODULATORS
CN102869660A (zh) 2010-02-17 2013-01-09 詹森药业有限公司 作为雌激素相关受体-α调节剂的氨基噻唑酮
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
TW201311679A (zh) 2011-08-04 2013-03-16 Takeda Pharmaceutical 含氮雜環化合物
CA2868311C (en) 2012-03-26 2021-06-22 Nippon Chemiphar Co., Ltd. Use of non-steroidal anti-inflammatory drugs (nsaids) and thiazolidinediones in the treatment of giant cell tumors occurring in a bone or soft tissue or of chondrosarcoma
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
JP6527822B2 (ja) 2013-09-25 2019-06-05 日本ケミファ株式会社 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020198537A1 (en) * 2019-03-28 2020-10-01 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x4 and related products and methods
CA3144891A1 (en) * 2019-07-04 2021-01-07 Lead Pharma Holding B.V. Estrogen-related receptor alpha (err.alpha.) modulators
CN112538038B (zh) * 2019-09-20 2022-05-20 暨南大学 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用
KR20220066822A (ko) 2020-11-16 2022-05-24 경북대학교 산학협력단 골 질환 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
JP2001072592A (ja) * 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
CA2406383A1 (en) 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2006004555A1 (en) 2004-06-30 2006-01-12 Paysetter Pte Ltd System and method for facilitating transfer of physical money and/or credit
AU2005275279A1 (en) * 2004-07-14 2006-02-23 Janssen Pharmaceutica N.V. Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
CA2583271C (en) 2004-10-22 2014-05-20 Exelixis, Inc. Benzylthiazolone inhibitors of estrogen-related receptors (err)

Also Published As

Publication number Publication date
UA98484C2 (ru) 2012-05-25
US20080221179A1 (en) 2008-09-11
CL2008000667A1 (es) 2008-11-03
AU2008222755A1 (en) 2008-09-12
IL200759A0 (en) 2010-05-17
EA016887B1 (ru) 2012-08-30
US8580832B2 (en) 2013-11-12
CN101679327A (zh) 2010-03-24
CA2680212A1 (en) 2008-09-12
EP2134698A1 (en) 2009-12-23
TW200902506A (en) 2009-01-16
AU2008222755B2 (en) 2013-05-02
JP2010520308A (ja) 2010-06-10
MX2009009520A (es) 2009-11-18
BRPI0808776A2 (pt) 2014-08-19
NZ579417A (en) 2012-02-24
EA200970839A1 (ru) 2010-04-30
WO2008109737A1 (en) 2008-09-12
KR20090128454A (ko) 2009-12-15

Similar Documents

Publication Publication Date Title
AR065657A1 (es) DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS.
AR065656A1 (es) Tiazolidindionas n-alquiladas fenoxi sustituidas como moduladoras del receptor alfa relacionado con estrogeno
ECSP099614A (es) Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno
AR080207A1 (es) Aminotiazolonas como modulares de los receptores de estrogenos alfa
JP2010520308A5 (OSRAM)
JP2010520306A5 (OSRAM)
RU2016143333A (ru) Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
AR066904A1 (es) Pirrolopiridinas y pirazolopiridinas sustituidas como moduladores de las quinasas, una composicion farmaceutica que las incluye y su uso en el tratamiento del cancer
JP2014528466A5 (OSRAM)
CN112955454A (zh) 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
MX2015017343A (es) Derivados de pirrolopiridina o pirazolopiridina.
JP2010508262A5 (OSRAM)
JP2010525023A5 (OSRAM)
JP2012526842A5 (OSRAM)
MX2009010790A (es) Derivados de heteroarilo biciclico fusionados.
JP2013520473A5 (OSRAM)
AR055202A1 (es) Derivados de imidazolcarboxamida como inhibidores de fructosa -1,6- biofosfatasa y composiciones farmaceuticas que los contienen
SI3166925T1 (en) Isoindoline derivatives for use in treating a viral infection
RU2017121460A (ru) Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение
AR080206A1 (es) Aminotiazolonas como moduladores del receptor alfa relacionados con estrogeno
MX2025010782A (es) Compuestos de piridazina, su preparacion y sus usos terapeuticos
AR045721A1 (es) Derivados de pirrol 2,5 diona como moduladores de receptores hormonales de higado
ES2945062T3 (es) Derivados de ácido barbitúrico novedosos, su preparación y uso de los mismos como inhibidores de la transmigración de leucocitos y para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias y cáncer
AR076516A1 (es) Derivados de oxa-azaespiro[3.3]heptan-6-ilo, metodo e intermediarios para su preparacion, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor mch1.
JP2008530242A5 (OSRAM)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal